Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Short term Debt (2022 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Short term Debt for 4 consecutive years, with $37944.0 as the latest value for Q2 2025.

  • On a quarterly basis, Short term Debt fell 75.07% to $37944.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $37944.0, a 75.07% decrease, with the full-year FY2024 number at $110517.0, down 26.37% from a year prior.
  • Short term Debt was $37944.0 for Q2 2025 at Inhibikase Therapeutics, down from $74772.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $152224.0 in Q2 2024 to a low of $37944.0 in Q2 2025.
  • A 4-year average of $129475.2 and a median of $146368.5 in 2022 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: rose 4.92% in 2023, then tumbled 75.07% in 2025.
  • Inhibikase Therapeutics' Short term Debt stood at $145836.0 in 2022, then grew by 2.92% to $150095.0 in 2023, then dropped by 26.37% to $110517.0 in 2024, then tumbled by 65.67% to $37944.0 in 2025.
  • Per Business Quant, the three most recent readings for IKT's Short term Debt are $37944.0 (Q2 2025), $74772.0 (Q1 2025), and $110517.0 (Q4 2024).